Context Therapeutics Inc.
News
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
Globe Newswire The appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipeline strategyPHILADELPHIA, Sept. 04...\n more…
We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business Growth
Simply Wall St Just because a business does not make any money, does not mean that the stock will go down. By way of example, Context...\n more…
Research Analysts Set Expectations for Context Therapeutics Inc.'s Q3 2024 Earnings (NASDAQ:CNTX)
Ticker Report Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Equities research analysts at HC Wainwright upped their Q3 2024 earnings per share (EPS) estimates for Context Therapeutics in a research...\n more…
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
Globe Newswire Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations Appointments support the development of the Company's two clinical-stage T cell...\n more…
Buy Rating Justified by Context Therapeutics' Strategic Acquisition and Promising T Cell Engager Pipeline
TipRanks Financial Blog Analyst Jason McCarthy of Maxim Group reiterated a Buy rating on Context Therapeutics (CNTX - Research Report), retaining the price target of $10.0...\n more…
Context Therapeutics (NASDAQ:CNTX) Given "Buy" Rating at HC Wainwright
Ticker Report HC Wainwright reiterated their buy rating on shares of Context Therapeutics (NASDAQ:CNTX - Free Report) in a report issued on Wednesday morning, Benzinga reports. They currently have a $5.00 price...\n more…